Audra Jackson, MD
Family Medicine · Fort Smith, ARNPI 1093815268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Amgen at 27.1% of the total. Reporting peaked in 2019 at $553 and has fallen 83.1% since, to $94 in 2025.
Across 78 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$345
- AbbVie$124
- AstraZeneca$101
- Takeda Pharmaceuticals U.S.A., Inc.$99
- Novo Nordisk$77
- Abbott$76
- plus $452 from 17 others
What the payments were for
- Food & beverage$1,275100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $345 |
| AbbVie(2 entities) | 7 | $124 |
| AstraZeneca(2 entities) | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $99 |
| Novo Nordisk | 4 | $77 |
| Abbott | 4 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Lilly USA, LLC | 4 | $58 |
| Avanir Pharmaceuticals, Inc. | 4 | $56 |
| Exact Sciences | 2 | $33 |
| GSK | 2 | $32 |
| Novartis | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Sanofi | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,275 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $81,946 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $43,717 |
| EliquisApixaban | 34 | $33,153 |
| XareltoRivaroxaban | 30 | $23,088 |
| TrulicityDulaglutide | 18 | $17,794 |
| JardianceEmpagliflozin | 23 | $17,075 |
| MyrbetriqMirabegron | 17 | $14,470 |
| FarxigaDapagliflozin Propanediol | 13 | $13,023 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $12,254 |
| TradjentaLinagliptin | 14 | $11,005 |
| JanuviaSitagliptin Phosphate | 14 | $9,604 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,312 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,952 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,935 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $77 | $81,94659 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $32 | $55,97186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $15 | $28,08037 claims |
| AstraZenecaFarxiga, Symbicort | $101 | $17,97525 claims |
| Lilly USA, LLCTrulicity | $58 | $17,79418 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $14,47017 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $2,102214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Fort Smith
- Glenn GibbonsFort Smith$179K
- Allen BeachyFort Smith$21K
- Michael CallawayFort Smith$15K
- Luc BalisFort Smith$10K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Hunter CarringtonHot Springs$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.